Revolution or mirage? Controversy surrounds new Alzheimer’s medicine

Paris –
Two new medicine, the primary able to slowing down the debilitating development of Alzheimer’s illness, have develop into embroiled in one of many greatest medical controversies lately.

For their defenders, the medicine lecanemab and donanemab characterize the primary actual likelihood to combat the illness after a long time of analysis — for detractors, they’re one other disappointment after an extended line of pricey failures.

“We have turned a nook” thanks to those remedies, stated British biologist John Hardy, who has been learning Alzheimer’s because the Nineteen Nineties.